Dr. Johnson is a professor of regulatory strategy at Northeastern University and Senior Director of Regulatory Strategy at Roivant Sciences, where she leads IND-enabling strategy for a variety of novel biotech and medtech products. She has over 16 years experience in global clinical trials, and previously held senior clinical and regulatory positions at IQVIA and GE Healthcare. She has authored over 20 publications, including on GCP and clinical trial strategy for medical devices and complex biologic products.
Angela Johnson
